Patent Application
20150196359
This application relates to methods for delivery of sub-surface arrays of absorber materials and methods of light irradiation therapy.
Photoaging is aging of skin with exposure to ultraviolet (UV) light. UV exposure can cause appearance of wrinkles. Also, with aging, skin can become lax. Both conditions can be improved by remodeling of the collagen to decrease the appearance of wrinkles. Successful treatments including demabrasion, chemical peels, and CO2 or Er:YAG laser resurfacing have been developed with excellent results. However, the side effects of oozing, bleeding, crusting, erythema, etc. as a healing response to the contiguous bulk thermal injury make such therapies less attractive. The second generation technology involved cooling of the surface and performing sub-surface thermal injury. Here, results were inadequate when the side effects profile and pain were kept to minimum. The third generation technology was the fractional treatment of skin wherein plugs of skin were removed or heated via ablative or non-ablative laser or mechanical sharp hollow needles. This minimizes side effects with acceptable results. However, the best results of fractional treatments are noted when high coverage is seen but the side effects can become problematic.
While certain approaches have been attempted, improvements are still needed in the field of treatment for lax skin and wrinkles.
The present invention relates to a method of treating at least one of aging and photoaging effects on skin. The method comprises injecting an amount of light absorbing material at a target zone beneath the skin in a predetermined pattern at a predetermined depth; and irradiating the light absorbing material to selected wavelengths of light, thereby causing at least one zone of thermal injury. Injecting can comprise injecting using a single needle or a microneedle array. When using a microneedle array, injecting can comprise depressing a reservoir in fluid connection with at least one of the needles in the array. The depressing can be performed manually or using a delivery device. The predetermined pattern can comprise regularly spaced rows and columns or the pattern can be irregular. The light absorbing material can be configured to absorb light at a wavelength of about 800 nm to about 1,200 nm. Irradiating the light absorbing material can comprise exposing the light absorbing material to light with a wavelength band of about 700 to about 1,200 nm. Injecting an amount of light absorbing material can comprise injecting at a depth of about 50 microns to about 2 mm. A diameter of the thermal damage zone can be about 50 microns to about 1 mm. Irradiating the light absorbing material can cause a plurality of zones of thermal injury, and a density of the thermal damage zones can be about 10 per cm2 to about 15,000 per cm2. An absorption coefficient in the target zone can be about 1.0 to about 1,000 (l/cm).
In another aspect, a device for treating skin is provided. The device comprises an array of microneedles; and a reservoir configured to hold fluid comprising a light absorbing material fluidly connected to at least one of the microneedles. The array can comprise microneedles in regular rows and columns or in an irregular pattern. The device can be contoured to match to a treatment site of a patient. The device can be a platform comprising a large microneedle array or a plurality of microneedle arrays. The device can comprise at least two reservoirs, each reservoir fluidly connected to at least one microneedle. The device can comprise a rectangular or ovular shape.
The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
One area of development in aging skin treatment includes methods for attempting to provide levels of more intense injury but in a sub-surface location in a fractional mode while while leaving the top skin viable. One particular approach is with ultrasound. More specifically, there have been attempts with focused ultrasound (e.g., Ulthera). However, the dimensions of the zones of thermal injury are limited by the wavelength of the ultrasound waves. There still remains a need for more precise, but intense, injury to sub-surface target sites without the inherent limitations of the methods described above.
In one aspect of the present invention, control over the amount and spread of the sub-surface thermal lesion can be obtained by injecting, in an array pattern, doses of a suspension of microparticles underneath the skin. In one aspect of the present invention, injecting in an array pattern, in the microliter range of suspension, underneath the skin in the region for therapy can be performed. The amount of suspension per dose can be controlled by the amount of injection or by the size of the delivery device. In addition, the depth and the lesion-to-lesion distance may also be varied based on patient need or desired therapeutic outcome. The concentration of particles in the dose, amount of suspension per dose, the depth of injection, and/or the lesion to lesion distance can be adjusted to effect a desired treatment outcome.
In some embodiments of the present invention, a composition of microparticle chromophores (light energy adsorbing materials) are injected into the sub-surface of the skin of a person needing or desiring treatment. In a preferred embodiment, the microparticle chromophores composition comprises unassembled plasmonic nanoparticles. Such plasmonic nanoparticles might include nanorods, hollow nanoshells, silicon nanoshells, nanoplates, nanorice, nanowires, nanopyramids, nanoprisms, nanoplates nanoplates, solid nanoshells, hollow nanoshells, nanorods, nanorice, nanospheres, nanofibers, nanowires, nanopyramids, nanoprisms, nanostars and other configurations known to those skilled in the art. The plasmonic nanoparticles are generally of a size from 1 to 1000 nm, although it is preferred that the plasmonic nanoparticles are of a size between about 100 and 300 nm. The plasmonic nanoparticles typically comprise silver, gold, nickel, copper, titanium, silicon, galadium, palladium, platinum, or chromium. Such plasmonic nanoparticles generally have a peak adsorption in the near infra-red region of the electromagnetic spectrum.
In a further preferred embodiment, the injected composition comprises plasmonic nanoparticles such as gold nanoshells having a silica core and a gold shell (diameter 150 nm). In a still further preferred embodiment, nanoshells used are composed of a 120 nm diameter silica core with a 15 micron thick gold shell, giving a total diameter of 150 nm. Such nanoshells may be covered by a 5,000 MW PEG layer. The PEG layer prevents and/or reduces nanoshell aggregation, thereby increasing the nanoshell suspensions stability and shelf-life.
The composition comprising plasmonic nanoparticles may have a nanoparticle concentration in a range of about 109 to about 1016 nanoparticles per ml. Typically, the composition comprising plasmonic nanoparticles may have a nanoparticle concentration in a range of about 1010 to about 1013 nanoparticles per ml. Such nanoparticle concentrations are calculated from the optical density of the composition at its peak absorption wavelength. Compositions of plasmonic nanoparticles used in the present invention will generally have an optical density between about 0.05 and about 5000.
In some embodiments, an individual needle or syringe can be used to produce array patterns.
In one aspect, very small amounts are needed to get the desired effect. Typical amount may be 10 nl per injection when the absorption coefficient is 5 cm−1. The range can be about 0.1 to 1,000 nl or about 1 to 100 nl. The absorption coefficient can be about 1 cm−1 to 1,000 cm−1. In one particular aspect, there is provided light absorbing materials in the near infrared (IR) range, e.g., about 700 to about 1,200 nm. For example, the light absorbing material can be configured to absorb at about 755 nm, about 800 nm, about 810 nm, or about 1,064 nm. Such materials can be used with intense pulsed light instruments (IPLs) with a wavelength band of about 700 to about 1,200 nm. Where the light absorbing materials are plasmonic gold nanoshells, the laser may be tuned to the nanoshell's absorption peak (40-50 J/cm2, 30-ms, 9×9 mm, LightSheer (800 nm)).
It is preferred that the thermal injury produced by the process of the present invention is substantially confined to a region, an “island,” surrounding the injected light absorbing material. In certain preferred embodiments of the present invention, the duration of the laser pulse is the same as, or less than, the thermal relaxation time of the zone of the light absorbing material. It is preferred that the duration of the laser pulse is between about 0.1 ms and about 200 ms. Such pulses are believed to produce the desired islands of injury.
The absorption coefficient in the target zone can be in the range of about 1.0 to about 1,000 (l/cm). The depth of the injections and subsequent thermal lesions can be about 50 microns to about 2 mm. The depth can depend on the anatomical site of treatment and/or a skin thickness of the patient. A diameter of the thermal damage zone can range from about 50 microns to about 1 mm. The diameter of the zone can depend on the amount of suspension injected beneath the skin. The density of the thermal damage zone can range from about 10 per cm2 to about 15,000 per cm2. The density of thermal damage ones can depend on the diameter of the zone, or the amount of suspension injected.
In addition to individual injection of the particle pattern, an array of microneedles can be used to inject the material to the desired depth within the skin. In some embodiments, the microneedle array particle delivery device is a patch based reservoir and needle array that may be provided in any of a wide variety of sizes, shapes and configurations.
As noted above, in some embodiments, the pattern comprises irregularly spaced rows and columns. The pattern of injection can comprise a generally irregular pattern (e.g., based on individual patient characteristics or desired treatment outcome). The pattern of injection can be shaped in other ways as well. For example, the pattern may be circular, rectangular, ovular, etc. The pattern can be selected based on patient anatomy and/or desired treatment outcome.
The needles 304 can be sized so that they are all a same length and gauge. In some embodiments, the needles 304 have varying lengths and/or gauges. The needles can be between about 50 microns and about 2 mm long. The relative locations of needles with different depths and/or gauges can be selected based on the anatomy, the anatomy of a particular patient, and/or a desired treatment outcome.
The microneedle array 300 shown in
As described in
In some embodiments, more than one microneedle array can be used at a time.
In some embodiments, the reservoirs are pressed manually to release the light absorbing materials. In some embodiments, a delivery device can be used.
The device can provide a way to adjust the volume of the injected material in the needle set. For example, a delivery device including a trigger can be used to depress a reservoir. A squeeze of a trigger can advance a plunger in the delivery device by a known distance that is controllable, thus adjusting the volume injected.
Similarly, light absorbing particles can be injected into sweat glands and then the skin can be treated with light to thermally damage and inactivate the glands to treat hyperhidrosis. The damage profile can be controlled via control of density, depth, and amount per injection.
In one aspect, the skin in the treatment area has been damaged by burns or includes a skin graft used to repair burned skin. The specific injection patterns, materials and density described herein adapted and configured to promote healing of burn skin or adaptation to skin graft or grafted region.
A variety of different formulations and compositions may be used to provide the activatable particles for the uses described herein. The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. In another aspect, the operation of the delivery device (i.e., delivery by injection of particles by any suitable means) for the delivery of a delivery fluid precedes or follows another treatment or another desired therapy. In this case, the operation and use of the delivery device is one part of a multi-part therapy. In one specific example of a multiple part therapy is the use of the delivery system to deliver a fluid, a formulation particles, shells, pharmaceuticals, liposomes, other treatment agents or pharmacologic materials onto, into or within a structure within a treatment or delivery site followed by a further treatment of the delivery or treatment site. In addition to the examples above, one specific example the further treatment is providing an activating energy to a fluid, a formulation or a pharmacologic material. Exemplary fluids, formulations and treatments are described in U.S. Pat. No. 6,183,773; U.S. Pat. No. 6,530,944; U.S. Published Patent Application US 2013/0315999 and U.S. Published Patent Application US 2012/0059307, each of which is incorporated herein in its entirety. Additionally or optionally, one or more of the delivery device operating parameters, and/or methods of use of the delivery system described herein may be modified based upon one or more characteristics of the delivery fluid, a component of the delivery fluid or a particle within the delivery fluid being used. In some embodiments, the particle being delivered may include one or more of, for example, nanorods, nanoshells, nanoprisms, dyes such as rose Bengal, ICG, methylene blue.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements, these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical range recited herein is intended to include all sub-ranges subsumed therein.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
This application claims the benefit or priority under 35 U.S.C. §119(e) of U.S. Provisional Application Nos. 61/926,097 filed Jan. 10, 2014, the entire contents of which are incorporated herein by this reference. All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61926097 | Jan 2014 | US |
